Alnylam Pharmaceuticals Inc. (ALNY) News
Filter ALNY News Items
ALNY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALNY News Highlights
- For ALNY, its 30 day story count is now at 4.
- Over the past 23 days, the trend for ALNY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- TOP are the most mentioned tickers in articles about ALNY.
Latest ALNY News From Around the Web
Below are the latest news stories about ALNYLAM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ALNY as an investment opportunity.
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023CAMBRIDGE, Mass., November 30, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top Places to Work in the "Largest Employer" category. This marks the third year in a row that Alnylam has taken the top spot in the Largest Employer category (> 1,000 employees). |
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular RiskCAMBRIDGE, Mass., November 11, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of patients with hypertension and high cardiovascular risk. The study results were presented during the American Heart Association (AHA) Scientific Sessions being held in Philadelp |
Wall Street Analysts Think Alnylam (ALNY) Could Surge 35.08%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Alnylam (ALNY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Alnylam to Webcast Presentations at Upcoming November Investor ConferencesCAMBRIDGE, Mass., November 07, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: |
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2023 Earnings Call TranscriptAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2023 Earnings Call Transcript November 2, 2023 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1.15, expectations were $-1.61. Operator: Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Q3 2023 Earnings Conference Call. At this time, participants are in a listen-only mode. After the […] |
Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration RevenuesAlnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration revenues. |
Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags SalesAgios' (AGIO) Q3 earnings beat estimates, but sales miss the same. |
Alnylam Pharmaceuticals Inc (ALNY) Reports 35% YoY Growth in Q3 2023 Net Product RevenuesCompany's Q3 2023 financial results highlight strong commercial performance and promising pipeline developments |
Alnylam (ALNY) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesWhile the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period ActivityCAMBRIDGE, Mass., November 02, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights. |